Literature DB >> 28194051

Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference.

Uday Yanamandra1, Navin Khattry2, Shaji Kumar3, Noopur Raje4, Arihant Jain1, Sundar Jagannath5, Hari Menon6, Lalit Kumar7, Neelam Varma1, Subhash Varma1, Tapan Saikia8, Pankaj Malhotra1.   

Abstract

The science of multiple myeloma (MM) and related plasma cell disorders is rapidly evolving with increased understanding of the disease biology and recent approval of the newer drugs widening the therapeutic armamentarium. Despite multiple international guidelines regarding the management of this disease, the practice of managing MM is not uniform amongst Indian physicians. There are challenges in management which are unique to the Indian patients. This review discusses these challenges and the consensus of the nation-wide experts in dealing with the same. We also briefly highlighted the perspective of international experts as discussed in the Myeloma State of the Art conference held in September 2016 at PGI, Chandigarh. An Indian Myeloma Academic Groupe (IMAGe) group was formed to strengthen the research, create awareness about myeloma and related disorders and form consensus guidelines/ recommendations that can be adapted to the Indian Scenario.

Entities:  

Keywords:  Consensus; Indian scenario; Multiple myeloma; Plasma cell dyscrasia

Year:  2017        PMID: 28194051      PMCID: PMC5280871          DOI: 10.1007/s12288-016-0773-9

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  18 in total

Review 1.  Maintenance therapy for multiple myeloma in the era of novel agents.

Authors:  Thierry Facon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2015

2.  India's Aspirations for Universal Health Coverage.

Authors:  K Srinath Reddy
Journal:  N Engl J Med       Date:  2015-07-02       Impact factor: 91.245

Review 3.  Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening.

Authors:  Robert A Smith; Deana Manassaram-Baptiste; Durado Brooks; Mary Doroshenk; Stacey Fedewa; Debbie Saslow; Otis W Brawley; Richard Wender
Journal:  CA Cancer J Clin       Date:  2015-01-08       Impact factor: 508.702

Review 4.  Allogeneic stem cell transplantation for multiple myeloma: is there a future?

Authors:  B Dhakal; D H Vesole; P N Hari
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

5.  Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

Authors:  Meletios Dimopoulos; Robert Kyle; Jean-Paul Fermand; S Vincent Rajkumar; Jesus San Miguel; Asher Chanan-Khan; Heinz Ludwig; Douglas Joshua; Jayesh Mehta; Morie Gertz; Hervé Avet-Loiseau; Meral Beksaç; Kenneth C Anderson; Philippe Moreau; Seema Singhal; Hartmut Goldschmidt; Mario Boccadoro; Shaji Kumar; Sergio Giralt; Nikhil C Munshi; Sundar Jagannath
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

6.  Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study.

Authors:  D H Vesole; M M Oken; C Heckler; P R Greipp; M S Katz; S Jacobus; G R Morrow
Journal:  Leukemia       Date:  2012-05-08       Impact factor: 11.528

7.  Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.

Authors:  Bruno Paiva; Maria-Belén Vidriales; Jose J Pérez; Gema Mateo; Maria Angeles Montalbán; Maria Victoria Mateos; Joan Bladé; Juan José Lahuerta; Alberto Orfao; Jesús F San Miguel
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

Review 8.  Vaccination in Multiple Myeloma: Review of Current Literature.

Authors:  Andinet Alemu; John O Richards; Martin K Oaks; Michael A Thompson
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-06-08

Review 9.  Optimal use of G-CSF administration after hematopoietic SCT.

Authors:  M Trivedi; S Martinez; S Corringham; K Medley; E D Ball
Journal:  Bone Marrow Transplant       Date:  2009-04-13       Impact factor: 5.483

Review 10.  Myeloma today: Disease definitions and treatment advances.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2016-01       Impact factor: 10.047

View more
  3 in total

1.  Myeloma at Cross Roads in India.

Authors:  Uday Yanamandra; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2018-10-08       Impact factor: 0.900

2.  Cost of Treatment of Multiple Myeloma in a Public Sector Tertiary Care Hospital of North India.

Authors:  Gunjeet Kaur; Shankar Prinja; Pankaj Malhotra; Deepesh P Lad; Gaurav Prakash; Alka Khadwal; Raja Ramachandran; Subhash Varma
Journal:  Indian J Hematol Blood Transfus       Date:  2017-07-03       Impact factor: 0.900

Review 3.  Allogeneic Hematopoietic Stem Cell Transplantation for Myeloma: Time for an Obituary or Not Just Yet!

Authors:  Sarita Rani Jaiswal; Suparno Chakrabarti
Journal:  Indian J Hematol Blood Transfus       Date:  2019-01-23       Impact factor: 0.900

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.